[CAS NO. 1655504-04-3] Orelabrutinib (ICP-022)
Please click "REQUEST A QUOTE" button if you need other sizes or
custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis,
please:
PRODUCTS SPECIFICATIONS [1655504-04-3]
Catalog
SLK-S9600
Brand
Selleck
CAS
1655504-04-3
DESCRIPTION [1655504-04-3]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 427.49 |
| Molecular Formula | C26H25N3O3 |
| SMILES | O=C(C1=CC=C(C2CCN(C(C=C)=O)CC2)N=C1C3=CC=C(OC4=CC=CC=C4)C=C3)N |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3392 mL | 11.6962 mL | 23.3924 mL |
| 5 mM | 0.4678 mL | 2.3392 mL | 4.6785 mL |
| 10 mM | 0.2339 mL | 1.1696 mL | 2.3392 mL |
| 50 mM | 0.0468 mL | 0.2339 mL | 0.4678 mL |
Description
Orelabrutinib (ICP-022) is a potent, orally active and irreversible inhibitor of . Orelabrutinib has potential antineoplastic activity.
Targets
| BTK [1] |
In vitro
Orelabrutinib potently inhibits BTK enzymatic activity with an IC50 value of 1.6 nM. In KINOMEscan assay conducted in parallel at 1 μM against a panel of 456 kinases, orelabrutinib only targets BTK with > 90% inhibition while ibrutinib inhibits additional many other kinases including EGFR, TEC and BMX, demonstrating orelabrutinib's superior kinase selectivity.
References
Powered by Arctom Copyright © 2025 Arctom.
All rights reserved.